Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMTNASDAQ:NBTXNASDAQ:SCPHNASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$4.44+1.8%$3.37$2.24▼$28.93$205.68M2.84825,903 shs59,044 shsNBTXNanobiotix$5.44+7.1%$3.66$2.76▼$6.00$256.40M0.3615,712 shs28,823 shsSCPHscPharmaceuticals$4.08$2.92$1.94▼$5.65$215.39M0.36367,436 shs32,446 shsVRCAVerrica Pharmaceuticals$0.61-2.6%$0.53$0.38▼$9.26$56.11M1.75584,064 shs15,624 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-2.46%+13.84%+31.33%+1.87%-81.28%NBTXNanobiotix+5.20%+11.10%+51.80%+64.66%-12.69%SCPHscPharmaceuticals-4.45%-0.97%+64.52%+36.45%-0.73%VRCAVerrica Pharmaceuticals+3.66%+4.72%+23.05%+5.40%-93.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFDMT4D Molecular Therapeutics2.977 of 5 stars3.33.00.00.04.21.70.6NBTXNanobiotix2.894 of 5 stars3.35.00.00.03.70.00.6SCPHscPharmaceuticals4.4331 of 5 stars3.54.00.04.23.21.70.6VRCAVerrica Pharmaceuticals4.4574 of 5 stars3.13.00.04.73.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56565.67% UpsideNBTXNanobiotix 2.50Moderate Buy$8.0047.06% UpsideSCPHscPharmaceuticals 3.00Buy$14.00243.14% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$8.001,218.83% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, SCPH, FDMT, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/14/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.005/9/2025FDMT4D Molecular TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.004/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)4/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$23K8,942.74N/AN/A$7.20 per share0.62NBTXNanobiotix-$11.61M-22.09N/AN/A($0.04) per share-136.00SCPHscPharmaceuticals$41.98M5.13N/AN/A$1.04 per share3.92VRCAVerrica Pharmaceuticals$7.18M7.82N/AN/A$0.47 per share1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$100.84M-$3.18N/AN/AN/AN/A-28.00%-26.16%8/14/2025 (Estimated)NBTXNanobiotix-$42.97MN/A0.00N/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals-$54.81M-$1.91N/AN/AN/A-264.60%-244.93%-68.56%8/13/2025 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.20N/AN/AN/A-625.06%-591.84%-141.63%8/13/2025 (Estimated)Latest VRCA, SCPH, FDMT, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/13/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A17.3317.33NBTXNanobiotixN/A1.42N/ASCPHscPharmaceuticals1.668.086.89VRCAVerrica PharmaceuticalsN/A1.341.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%NBTXNanobiotix38.81%SCPHscPharmaceuticals89.52%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%NBTXNanobiotix3.45%SCPHscPharmaceuticals4.78%VRCAVerrica Pharmaceuticals42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.33 million42.85 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableSCPHscPharmaceuticals3052.79 million47.28 millionOptionableVRCAVerrica Pharmaceuticals4092.49 million26.18 millionOptionableVRCA, SCPH, FDMT, and NBTX HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's WhyJune 10 at 1:49 AM | marketbeat.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 28, 2025 | globenewswire.comWall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Hold"May 24, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by AnalystsMay 24, 2025 | marketbeat.comResearch Analysts Offer Predictions for VRCA Q2 EarningsMay 20, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in PipelineMay 18, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference CallMay 13, 2025 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comVerrica Pharmaceuticals Reports Quarterly 2025 Financial ResultsMay 13, 2025 | globenewswire.com6VRCA : Earnings Outlook For Verrica PharmaceuticalsMay 13, 2025 | benzinga.comVerrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate UpdateMay 11, 2025 | msn.comVerrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025May 7, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Present at Citizens Life Sciences ConferenceMay 4, 2025 | msn.comVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New YorkApril 30, 2025 | globenewswire.comWhy Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%April 10, 2025 | aaii.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comVerrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1April 8, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025April 7, 2025 | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)April 5, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of DirectorsApril 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRCA, SCPH, FDMT, and NBTX Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$4.44 +0.08 (+1.83%) As of 10:21 AM Eastern4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Nanobiotix NASDAQ:NBTX$5.44 +0.36 (+7.09%) As of 10:14 AM EasternNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.scPharmaceuticals NASDAQ:SCPH$4.08 0.00 (0.00%) As of 10:22 AM EasternscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$0.61 -0.02 (-2.63%) As of 10:21 AM EasternVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alibaba’s Dip Is a Gift—Here’s the Price That Matters GameStop Turns a Profit, But Core Business Keeps Shrinking Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
